Episode 288: APCCC #3: Controversies aro...

En este episodio se abordan los resultados más recientes del ensayo fase 3 LITESPARK 011 (belzutifan + lenvatinib frente a cabozantinib). Brian, Tom y Bob Motzer analizan la eficacia, seguridad y las implicaciones de los resultados para la secuenciación de tratamiento. 

En esta discusión se exploran los últimos avances en el tratamiento adyuvante del cáncer de riñón, centrándose en los recientes resultados del ensayo fase 3 de belzutifan en combinación con pembrolizumab (LITESPARK-022). Se abordan los pormenores del mecanismo de acción, el desar ... Show More

En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo cisplatino-elegible, centrándose en la eficacia de EV-Pembro en comparación con cisplatino-gemcitabina. Exploran la SLE, SG y las imp ... Show More

<p class="" style="white-space:pre-wrap;">Last, but not least, in our multidisciplinary discussions regarding the management of prostate cancer, we are thrilled to present a special episode featuring soon-to-be attending Radiation Oncologist Dr. Jacob Hall. Dr. Hall is a senior R ... Show More

<p>Today’s episode is part 2 of our prostate cancer series, and will focus on the important details regarding treatment options for castrate sensitive and resistant prostate cancer.</p> 

New research on prostate cancer screening and diet 

<p>This is the first of a two part episode on prostate cancer. This episode will cover localized prostate cancer, including the diagnostic work-up, staging and treatment. </p> 

Send a textNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob break down the essential clinical and pathophysiologic features of Prostate Cancer, one of the most common malignancies affecting men worldwide.We begin with the epidemiology and risk factors, highligh ... Show More

March is colon cancer awareness month so in today's episode, I discuss oncologic treatment options for colorectal cancer with Dr. Hardeep Phull. Dr. Phull is Medical Director of Oncology at Palomar Health and Clinical Instructor at the University of California San Diego. He gives ... Show More

Olympic cyclist Sir Chris Hoy is calling for more prostate cancer testing after he was diagnosed with terminal cancer. Prostate cancer can often present without symptoms, and for people like Sir Chris, this can mean it isn't diagnosed until it has spread and become incurable. Unl ... Show More

<p>This week, we are joined by Dr. Nina Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology Service, UT Southwestern Medical Center in Dallas, Texas, for a discussion about the role of radiation in colorectal cancer, with an emphasis on the role of radia ... Show More

About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Join Lauren Bright Pacheco at the 2024 ASCO Annual Meeting in Chicago, as she investigates the advancements in prostate cancer care.  Dr. Mohammad Atiq shares ways innovative treatments are paving the ... Show More